Avomeen to Become Element
In early 2021 , Avomeen was acquired by Element Materials Technology, advancing Element’s commitment to providing best-in-class scientific solutions to the vital Life Sciences sector, with a focus on true strategic partnerships that support the entire product development lifecycle, from drug discovery and development to regulatory product approval pathways.
Over the past year, we have been working behind the scenes to integrate Avomeen into the Element Materials Technology Life Sciences business unit. On February 1, 2022, Avomeen’s name will change to Element. We will continue to provide the same exceptional subject matter expertise, quality testing, and customer service you expect from us, in addition to an ever-deepening bench of scientific and regulatory expertise within Element Life Sciences.
We will share more details about what changes you can expect in the coming weeks. However, as we will be changing only our name, there will be no planned impact to contracts, agreements, registrations, and many other areas of business. As always, we remain committed to supporting you as a full-service CDMO partner, with a resolute commitment to scientific excellence, quality and regulatory compliance. Please keep an eye out for communications closer to February 1.
Total Page Views: 958
